Loading...
NPI 1649407792 · Bremerton, WA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Laboratory Services Cooperative is a clinical medical laboratory provider located in Bremerton, Washington. This profile covers 2 Medicare and 12 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Laboratory Services Cooperative |
| Address | 723b Ne Riddell Rd |
| City | Bremerton |
| State | WA |
| ZIP | 98310 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 16, 2009 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $64M |
| Medicare | $2.2K |
This entity is effectively a Medicaid-centric laboratory: reported Total Medicare revenue is $2.2K versus Total Medicaid revenue of $64M, indicating Medicaid dominates its billing footprint by several orders of magnitude and that Medicare activity is negligible in scale compared with Medicaid. Analysts should treat this provider as essentially single-payer (Medicaid) for operational and network impact assessments.
Revenue is highly concentrated in a very small set of diagnostic tests for each payer. Precomputed aggregates show the top 3 Medicare codes account for 100.0% of Medicare revenue and the top 3 Medicaid codes account for 97.0% of Medicaid revenue, so the provider’s financial profile is driven almost entirely by a few lab tests.
The provider’s code mix identifies it as a high-volume sexually transmitted infection (STI) diagnostic lab with supportive infectious-disease assays: the Medicaid top codes are 87591, 87491, and 87661 (NAATs for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis respectively), and additional Medicaid lines include HSV testing (87529) and multi-agent NAAT panels (87801). This mix implies a centralized, high-throughput molecular testing operation focused on NAAT and immunoassay workflows rather than diverse anatomic pathology or clinical chemistry services.
On Medicaid the provider is a statewide dominant outlier for its core STI tests: 87591 shows 880.5K claims and $27.3M revenue (42.7% of this provider's total Medicaid revenue) and ranks #1 of 116 in-state (100th percentile; extreme outlier, far above typical state volume); 87491 shows 878.4K claims and $27.2M revenue (42.6%) and ranks #1 of 118 in-state (100th percentile; extreme outlier, far above typical state volume); 87661 shows 267.4K claims and $7.5M revenue (11.7%) and ranks #1 of 63 in-state (100th percentile; extreme outlier, far above typical state volume). These ranks indicate the provider is the dominant in-state executor of Medicaid-paid NAAT STI testing.
By contrast, the provider is a modest participant on Medicare for the same test types. Medicare top codes 87491 and 87591 each account for 50.0% of the provider’s total Medicare revenue (each ~ $1.1K) but rank low nationally (87491 ranks #373 of 530, 29th percentile; 87591 ranks #369 of 514, 28th percentile) and are explicitly labeled typical or unremarkable volume. Given Total Medicare revenue of $2.2K, the Medicare business line is immaterial compared with Medicaid.
The raw claim volumes reported on Medicaid for core NAATs are extremely large and consistent with centralized, automated processing: examples include 880.5K claims for 87591 and 878.4K claims for 87491, each producing multi‑million dollar Medicaid revenues. These volumes suggest the provider operates high-throughput specimen accessioning, batch NAAT platforms, and likely has payer relationships or contracts that route large Medicaid testing volumes to this site.
Secondary lines on Medicaid are present but peripheral to the revenue pool. Codes such as 87529 (15.4K claims, $616.6K revenue; ranks #1 of 22), 87801 (12.4K claims, $572K revenue; ranks #3 of 32, 94th percentile), and syphilis/HSV immunoassays like 86780 (23.7K claims, $237K revenue; ranks #4 of 75, 96th percentile) appear as ancillary testing lines that together contribute modest shares of revenue relative to the three NAAT leaders. These ancillary codes confirm a broader infectious-disease testing menu but do not materially change the provider’s NAAT concentration.
The provider has a long tenure in national enrollment, with NPI enumerated on 2009-06-16 (~17 years ago), which supports the interpretation of an established operation rather than a new entrant; the combination of long enrollment and extreme Medicaid volumes strengthens the case that this entity is an established centralized lab servicing high Medicaid STI testing demand in-state.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 30 | $30 | $1.1K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 30 | $30 | $1.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 880,540 | $30 | $27.3M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 878,430 | $30 | $27.2M |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 267,370 | $30 | $7.5M |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 15,410 | $40 | $616.6K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 12,440 | $50 | $572K |
| 86780 | The lab analyst performs an immunoassay to evaluate the patient’s serum for antibodies to Treponema pallidum, a spiral shaped bacteria called a spirochete, that causes syphilis. | 23,700 | $10 | $237K |
| 87800 | The lab analyst performs a test for multiple infectious organisms in one sample using direct nucleic acid probe technique. | 5,390 | $30 | $183.3K |
| 86696 | The lab analyst performs an immunoassay to evaluate the patient’s serum or cerebrospinal fluid, CSF, for antibodies to type 2 herpes simplex (HSV–2). | 10,290 | $10 | $144K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 3,250 | $30 | $81.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2,870 | $20 | $63.2K |
Showing 1–10 of 12
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
12 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 1 | 120 | 2,040 | $30 | $464.9K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 1 | 120 | 2,020 | $30 | $441.1K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 1 | 60 | 1,340 | $30 | $208.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 3 | 30 | 220 | $40 | $103.3K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 35 | 40 | 620 | $30 | $76.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 10 | 80 | 180 | $40 | $65K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 1 | 20 | 420 | $30 | $57.5K |
| 86780 | The lab analyst performs an immunoassay to evaluate the patient’s serum for antibodies to Treponema pallidum, a spiral shaped bacteria called a spirochete, that causes syphilis. | 4 | 80 | 810 | $10 | $50.4K |
| 86696 | The lab analyst performs an immunoassay to evaluate the patient’s serum or cerebrospinal fluid, CSF, for antibodies to type 2 herpes simplex (HSV–2). | 3 | 30 | 420 | $10 | $38.4K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 3 | 10 | 850 | $20 | $31.4K |
Showing 1–10 of 12
Other providers in the same ZIP code as Laboratory Services Cooperative, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Olympic Ambulance Service Inc. | WA | Land Ambulance | $6M | $14.9M |
| Matthew Callan | WA | Oral and Maxillofacial Surgery (Dentist) | $0 | $5.4M |
| Franciscan Medical Group | WA | Internal Medicine Physician | $0 | $4.5M |
| Baart Behavioral Health Services, Inc. | WA | Substance Use Disorder Rehabilitation Clinic/Center | $133.9K | $701.3K |
| Manas Jain | WA | Urology Physician | $489.2K | $0 |
| Satyavardhan Pulukurthy | WA | Interventional Cardiology Physician | $394.9K | $0 |
| Christopher Johnson | WA | Cardiovascular Disease Physician | $361.2K | $0 |
| Gary Gretch | WA | Internal Medicine Physician | $315.7K | $0 |
| Kenton Sorensen | WA | Ophthalmology Physician | $312.2K | $0 |
| Ravi Kilaru | WA | Cardiovascular Disease Physician | $287.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.